Use of a personalized iterative score to evaluate risk of venous thromboembolism during pregnancy and puerperium.
Age Factors
Anticoagulants
/ administration & dosage
Female
Heparin
/ administration & dosage
Humans
Odds Ratio
Pregnancy
Pregnancy Complications, Cardiovascular
/ diagnosis
Prenatal Diagnosis
/ methods
Puerperal Disorders
/ diagnosis
Retrospective Studies
Risk Assessment
Risk Factors
Stockings, Compression
Venous Thromboembolism
/ diagnosis
Heparin
Low molecular weight
Pregnancy
Prevention
Puerperium
Risk score
Venous thromboembolism
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
25
04
2018
revised:
22
08
2018
accepted:
20
12
2018
pubmed:
24
12
2018
medline:
8
3
2019
entrez:
23
12
2018
Statut:
ppublish
Résumé
To determine whether a personalized iterative venous thromboembolism (VTE) risk score improved preventive prophylaxis during pregnancy and puerperium. An observational retrospective comparative study was conducted at single French hospital. Women who gave birth from February 1 to April 30, 2012 (n=557) or from February 1 to April 30, 2015 (n=512) underwent VTE risk assessment. The VTE risk score comprised known risk factors for this condition. Use of the VTE risk score at the first consultation increased the likelihood of appropriate treatment (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.2-1.9; P=0.002) and reduced the risk of undertreatment (OR 0.5, 95% CI 0.4-0.7; P<0.001). During hospitalization and puerperium, the VTE risk score increased the likelihood of appropriate treatment. The ORs were 6.2 (95% CI 2.1-18.9; P<0.001) and 5.4 (95% CI 4.1-7.2; P<0.001), respectively. The risk of undertreatment was also reduced at these time points. Use of the VTE risk score increased the number of appropriately treated patients during pregnancy and puerperium.
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-282Informations de copyright
© 2018 International Federation of Gynecology and Obstetrics.